Molecular defects in coagulation factor VIII and their impact on factor VIII function

Vox Sanguinis

Volumn 83, Issue 2, 2002, Pages 89-96

  Saenko, E L ^a,b   Ananyeva, N ^a   Kouiavskaia, D ^a   Schwinn, H ^c   Josic, D ^d   Shima, M ^e   Hauser, C A E ^f,g   Pipe, S ^h  

^a HOLLAND LABORATORY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Octophorma AG   (Switzerland)

^d Octapharma Pharmazeutika Produktions GmbH   (Austria)

^e NARA MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF LÜBECK   (Germany)

^g Octagene Biomed Laboratories GmbH   (Germany)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Conformational changes; Factor VIII; Haemophilia A; Mutations; Phospholipid binding; Surface plasmon resonance

Indexed keywords

BLOOD CLOTTING FACTOR 8; PHOSPHOLIPID; VON WILLEBRAND FACTOR;

CLINICAL PATHWAY; CONFORMATIONAL TRANSITION; ENZYME ACTIVITY; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOGENICITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

BLOOD COAGULATION; FACTOR VIII; HEMOPHILIA A; HUMANS; MUTATION; PROTEIN CONFORMATION;

EID: 0038052806     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2002.00183.x     Document Type: Review

References (64)

1. a in the activation of bovine factor X. J Biol Chem 1981; 256:3433-3442
2. Gilbert GE, Arena AA: Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-1-serine. J Biol Chem 1996; 271:11120-11125
3. Nesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ: The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 1988; 263:16467-16470
4. Saenko EL, Shima M, Sarafanov AG: Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex. Trends Cardiovasc Med 1999; 9:185-192
5. Fay PJ: Regulation of Factor VIIIa in the intrinsic Factor Xase. Thromb Haemost 1999; 82:193-200
6. Mann KG: Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82:165-174
7. Hoyer LW: Hemophilia A. N Engl J Med 1994; 330:38-47
8. Saenko EL, Scandella D: The acidic region of the light chain and the C2 domain together form a high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272:18007-18014
9. Regan LM, Fay PJ: Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem 1995; 270:8546-8552
10. 1689. J Biol Chem 2000; 275:25774-25780
11. Nogami K, Shima M, Hosokawa K, Suzuki T, Koide T, Saenko EL, Scandella D, Shibata M, Kamisue S, Tanaka I, Yoshioka A: Role of factor VIII, C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274:31000-31007
12. Saenko EL, Scandella D, Yakhyaev AV, Greco N: Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem 1998; 273:27918-27926
13. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS: Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75:1999-2004
14. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D: A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269:11601-11605
15. Healey JF, Barrow RT, Tamim HM, Lubin IM, Shima M, Scandella D, Lollar P: Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92:3701-3709
16. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL: Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402:439-442
17. Barrow RT, Healey JF, Jacquemin M, Saint-Remy J-M, Lollar P: Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 2001; 97:169-174
18. Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW: Four hydrophobic amino acids of the factor VIII, C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 227:6374-6381
19. Lenting PJ, van de Loo J-WHP, Donath M-JSH, van Mourik JA, Mertens K: The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271:1935-1940
20. Fay PJ, Beattie T, Huggins CF, Regan LM: Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269:20522-20527
21. Fay PJ, Scandella D: Human inhibitor antibodies specific for the factor VIII, A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274:29826-29830
22. Fay PJ, Mastri M, Koszelak ME, Wakabayashi H: Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXA. J Biol Chem 2001; 276:12434-12439
23. Fay PJ, Koshibu K: The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998; 273:19049-19054
24. Lollar P, Parker ET, Fay PJ: Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 1992; 267:23652-23657
25. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ: Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996; 271:6027-6032
26. Lapan KA, Fay PJ: Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997; 272:2082-2088
27. Lapan KA, Fay PJ: Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost 1998; 80:418-422
28. Saenko EL, Shima M, Gilbert GE, Scandella D: Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271:27424-27431
29. Gilbert GE, Drinkwater D, Barter S, Clouse SB: Specificity of phosphatidylserine-containing membrane binding sites for factor VIII. Studies with model membranes supported by glass microspheres (liposheres). J Biol Chem 1992; 267:15861-15868
30. Saenko E, Sarafanov A, Ananyeva N, Behre E, Shima M, Schwinn H, Josic D: Comparison of the properties of phospholipid surfaces formed on HPA and L1 biosensor chips for the binding of the coagulation factor VIII. J Chromatogr A 2001; 921:49-56
31. Raut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe T, Laub R: Modification of factor VIII in therapeutic concentrates after virus inactivation by virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost 1998; 80:624-631
32. Raut S, Weller L, Barrowcliffe T: Phospholipid binding of factor VIII in different therapeutic concentrates. Br J Haematol 1999; 107:323-329
33. Saenko E, Josic D, Stadler M, Sarafanov A, Lim Y-P, Shima M, Ananyeva N, Schwinn H: Molecular modifications in factor VIII concentrates produced from different plasma pools. Thromb Res 2001; 101:501-511
34. Laub R, Di Giambattista M, Fondu P, Brackmann H-H, Lenk H, Saenko E, Felch M, Scandella D: Inhibitors in German Hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of fVIII light chain. Thromb Haemost 1999; 81:39-44
35. Sawamoto Y, Prescott R, Zhong D, Saenko E, Mauser-Bunschoten E, Peerlinck K, van den Berg M, Scandella D: Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 1998; 79:62-68
36. Saenko EL, Scandella D: A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 1995; 270:13826-13833
37. Sandberg H, Almstedt A, Brandt J, Gray E, Holmquist L, Oswaldsson U, Sebring S, Mikaelsson M: Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85:93-100
38. Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H: A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69:240-246
39. Scandella D, Gilbert GE, Shima M, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Saenko E: Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipid binding site. Blood 1995; 86:1811-1819
40. Pock K, Rizzi A, Josic D: Use of high-resolution techniques for the characterization of clotting factor VIII. J Chromatogr A 1999; 852:175-188
41. Pock K, Jungbauer A, Kannicht C, Loster K, Buchacher A, Josic D: Electrophoretic analyses of clotting factor VIII concentrates. Anal Chim Acta 1998; 372:219-229
42. Sandberg H, Almstedt A, Brandt J, Castro VM, Gray E, Holmquist L, Lewin M, Oswaldsson U, Mikaelsson M, Jankowski MA, Bond M, Scoble HA: Structural and functional characterization of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38:4-12
43. Ashton RW, Scheraga HA: Preparation and characterization of anhydrothrombin. Biochemistry 1995; 34:6454-6463
44. Hill-Eubanks DC, Parker CG, Lollar P: Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin. Proc Natl Acad Sci USA 1989; 86:6508-6512
45. Hill-Eubanks DC, Lollar P: von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 1990; 265:17854-17858
46. Arai M, Inaba H, Higuchi M, Antonarakis SE, Kazazian HH Jr, Fujimaki M, Hoyer LW: Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372 histidine). Proc Natl Acad Sci USA 1989; 86:4277-4281
47. Shima M, Ware J, Yoshioka A, Fukui H, Fulcher CA: An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. Blood 1989; 74:1612-1617
48. Acquila M, Caprino D, Pecorara M, Baudo F, Morfini M, Mori PG: Two novel mutations at 373 codon of FVIII gene detected by DGGE. Thromb Haemost 1993; 69:392-393
49. Schwaab R, Oldenburg J, Lalloz MR, Schwaab U, Pemberton S, Hanfland P, Brackmann HH, Tuddenham EG, Michaelides K: Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Hum Genet 1997; 101:323-332
50. Gitschier J, Kogan S, Levinson B, Tuddenham EGD: Mutations of factor VIII cleavage sites in hemophilia A. Blood 1988; 72:1022-1028
51. Schwaab R, Ludwig M, Kochhan L, Oldenburg J, McVey JH, Egli H, Brackmann HH, Olek K: Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain. Thromb Res 1991; 61:225-234
52. 1689 detected by a novel ELISA. Br J Haemotol 1994; 86:106-111
53. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV: Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87:846-848
54. Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV: Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His 1954→Leu substitution in the factor VIII, A3 domain. Br J Haematol 1999; 105:1123-1126
55. Barrowcliffe TW: Methodology of the two-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl 1984; 41:25-38
56. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A: 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron microscopy. Blood 2002; 99:1-7
57. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook G: A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89:2413-2421
58. Pipe SW, Saenko E, Kaufman RJ: Mild hemophilia A caused by increased rate of factor VIII, A2 subunit dissociation: evidence for non-proteolytic inactivation of factor VIII in vivo. Blood 1999; 93:176-183
59. Pipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ: Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97:685-691
60. Shima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, Giles AR, Yoshioka A: The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of Haemophilia A patients with very low levels of Factor VIII activity (FVIII:C). Thromb Haemost 2002; 87:436-441
61. Pipe SW, Kaufman RJ: Factor VIII, C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 1996; 271:26571-25676
62. Nesbitt IM, Hinks JL, Sampson B, Kitchen S, Peake IR, Makris M, Goodeve AC: Discrepant one- and two-stage fVIII assays are very common in mild haemophilia A: correlation with fVIII gene mutations. Thromb Haemost 2001; (Suppl. Jul) OC195
63. Hakeos WH, Pipe SW, Saenko EL, Kaufman RJ: Hemophilia A mutations within the factor VIII, A2-A3 subunit interface destabilize fVIIIa and cause one-stage/two-stage activity discrepancy. Blood 2001; 96:532a
64. David D, Saenko EL, Santos IM, Johnson DJ, Tuddenham EG, McVey JH, Kemball-Cook G: Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r)). Br J Haematol 2001; 113:604